Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock 2023 Neurocrine Collaborative Agreement	Common Stock 2023 Novartis Collaboration Agreement	Common Stock	Additional Paid-In Capital 2023 Neurocrine Collaborative Agreement	Additional Paid-In Capital 2023 Novartis Collaboration Agreement	Additional Paid-In Capital	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit	2023 Neurocrine Collaborative Agreement	2023 Novartis Collaboration Agreement	Total
Stockholders' Equity, Beginning Balance at Dec. 31, 2021			$ 38			$ 442,259	$ (138)	$ (347,104)			$ 95,055
Shares, Outstanding, Beginning Balance at Dec. 31, 2021			37,918,395
Exercises of vested stock options						629					629
Exercises of vested stock options (in shares)			89,012
Vesting of restricted stock units (in shares)			456,219
Issuance of common stock under ESPP						672					672
Issuance of common stock under ESPP (in shares)			150,265
Stock-based compensation expense						9,153					9,153
Unrealized loss on available-for-sale securities							(81)				(81)
Net income (loss)								(46,408)			(46,408)
Stockholders' Equity, Ending Balance at Dec. 31, 2022			$ 38			452,713	(219)	(393,512)			59,020
Shares, Outstanding, Ending Balance at Dec. 31, 2022			38,613,891
Exercises of vested stock options			$ 1			1,851					1,852
Exercises of vested stock options (in shares)			385,655
Vesting of restricted stock units (in shares)			531,560
Issuance of common stock	$ 5			$ 31,116					$ 31,121
Issuance of common stock (in shares)	4,395,588
Issuance of common stock under ESPP						959					959
Issuance of common stock under ESPP (in shares)			111,639
Stock-based compensation expense						10,867					10,867
Unrealized loss on available-for-sale securities							171				171
Net income (loss)								132,330			132,330
Stockholders' Equity, Ending Balance at Dec. 31, 2023			$ 44			497,506	(48)	(261,182)			236,320
Shares, Outstanding, Ending Balance at Dec. 31, 2023			44,038,333
Exercises of vested stock options						388					$ 388
Exercises of vested stock options (in shares)			106,831								106,831
Vesting of restricted stock units			$ 1								$ 1
Vesting of restricted stock units (in shares)			515,303
Issuance of common stock		$ 2			$ 19,303					$ 19,305
Issuance of common stock (in shares)		2,145,002
Issuance of common stock and pre-funded warrants in connection with underwritten public offering			$ 8			93,465					93,473
Issuance of common stock and pre-funded warrants in connection with underwritten public offering (in shares )			7,777,778
Issuance of common stock under ESPP						1,172					1,172
Issuance of common stock under ESPP (in shares)			148,069
Stock-based compensation expense						14,462					14,462
Unrealized loss on available-for-sale securities							(359)				(359)
Net income (loss)								(65,002)			(65,002)
Stockholders' Equity, Ending Balance at Dec. 31, 2024			$ 55			$ 626,296	$ (407)	$ (326,184)			$ 299,760
Shares, Outstanding, Ending Balance at Dec. 31, 2024			54,731,316